BIO-B
Bio-Rad Laboratories IncNYSE
Healthcare • Medical Devices
Updated 8 days ago
Coverage limited
$365.08+8.33%
Close Aug 20, 2026
- Market cap
- $9.76B
- 1 month
- —
- 3 months
- —
- 1 year
- —
- Dividend
- No dividends on record
- Short interest
- 1 sharessettled Sep 30, 2026 · -50.0% since Aug 14, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $2.59B
- Net income
- $222.4M
- Free cash flow
- $353.1M
- Book value
- $7.17B
- Total debt
- $1.2B
- P/E
- 43.9×
- Price / sales
- 3.8×
- Price / book
- 1.4×
- FCF yield
- +3.6%
- Net margin
- +8.6%
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if BIO-B is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
1 top institutions tracked
as of 2026-Q2 (filed 2026-09-29)
Insider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 0
Largest 13-F holders · Q2 2026
5 filers reported a long position in BIO-B for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FLOW TRADERS U.S. LLC | $229K | 760 | -22.8% |
| MORGAN STANLEY | $214.3K | 712 | Unchanged |
| WELLS FARGO & COMPANY/MN | $50.4K | 170 | Unchanged |
| WHITTIER TRUST CO | $47.3K | 160 | Unchanged |
| UBS Group AG | $3.9K | 13 | Unchanged |
Get the Full Analysis for BIO-B
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.